On September 2, 2023, the 2nd ROC Science Brainstorming 24, focusing on the basic knowledge of macrophages and clinical transformation, was successfully held for the purpose of closely integrating production, education and research. Professor Wang Jianchuan of Shenzhen Bay Laboratory is visiting this period.

(Group photo of two professors)

Shenzhen Bay Laboratory - Professor Wang Jianchuan

Professor Wang Jianchuan is a leading researcher in the field, focusing on the structural analysis of therapeutic antibodies Daclizumab and Basiliximab, which are pivotal in managing immune rejection post-organ transplant, along with their antigen CD25 complexes. His work also encompasses the structure of p70S6K1, a key enzyme in the mTOR signaling pathway, and its interaction with specific small molecule inhibitors. Under the mentorship of the esteemed Professor Timothy A. Springer, a member of the National Academy of Sciences and a Lasker Basic Medical Research Award laureate at Harvard University, he delved into the intricacies of integrins, molecules crucial for cell adhesion. His scholarly work has graced the pages of top-tier journals including Nature Communications, PNAS, Cell Research, and Biochemical Journal. Beyond academia, Professor Wang has been instrumental in steering investments in prominent biopharmaceutical ventures, such as the pioneering domestic anti-COVID drug Azvudine from Henan Real Biotech and the pioneering anti-tumor nanoantibody Envafolimab by 3D Medicine.

        RocRock Biotechnology is steadfast in its commitment to the principle of mutual benefit, actively fostering deep synergies among industry, academia, and research institutions. We are dedicated to driving advancements in technology and contributing to the betterment of society. We anticipate more cross-disciplinary engagement opportunities and are confident that, through collective efforts in diverse sectors, we can unlock further marvels in the realms of biology and science.